QuatRx Pharmaceuticals - Top 20 VC deals of 2007

Company: QuatRx Pharmaceuticals
Based: Ann Arbor, MI
Amount: $44M
Round: Fifth
Investors: BankInvest, Bio Fund Management Oy, Catella Holding AB, Frazier Healthcare and Technology Ventures, Gatenbeck Zakrisson Group, Hercules Technology Growth Capital, InterWest Partners, Kearny Venture Partners, MPM Capital, Stockwell, T. Rowe Price Threshold Partnerships, TL Ventures, Twilight Venture Partners, Undisclosed Investor, Undisclosed Venture Firm, Venrock Associates

Scoop: The new round is being used to complete Phase III and Phase II clinical studies of QuatRx’s two endocrine programs, Ophena and fispemifene. Since receiving the funding, QuatRx announced positive results from one of Phase III study of Ophena. It is also conducting Phase I studies of its lipid-lowering compound, QRX-431. QuatRx was a 2007 Fierce 15 company

More News:
QuatRx raises $44M in fifth venture finance round. Report
QuatRx files for $86.2M IPO. Report

QuatRx Pharmaceuticals - Top 20 VC deals of 2007
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i